p = 0.001), lower PNI (< 45, HR = 3.19, p < 0.001), serum CEA (≥5 ng/ml, HR = 2.13, p = 0.001), serum CA19-9 (≥37 IU/ml, HR = 4.53, p < 0.001), tumor size (≥5 cm, HR = 1.56, p = 0.015), advanced TNM stage (stage III, HR = 2.27, p < 0.001), number of lymph node metastases (≥5, HR = 3.57, p < 0.001), signet-ring cell carcinoma (HR = 2.04, p = 0.001), tumor deposits (HR = 2.40, p < 0.001), vessel carcinoma emboli (HR = 2.26, p < 0.001), and adjuvant chemotherapy (HR = 2.98, p < 0.001). The gene discussed is CEACAM5; the disease is signet ring cell carcinoma.